The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Treatment of Refractory Disseminated Nontuberculous Mycobacterial Infection With Interferon Gamma: A Preliminary Report
Abstract
BACKGROUND: Studies conducted in vitro and in animals suggest that cytokine signals to monocytes or macrophages by interferon gamma are important in the containment and clearance of disseminated nontuberculous mycobacterial infections. METHODS: We studied seven patients with refractory, disseminated nontuberculous mycobacterial infections who were not infected with the human immunodeficiency virus. Three patients were from a family predisposed to the development of Mycobacterium avium complex infections; four patients had idiopathic CD4+ T-lymphocytopenia. Their infections were culture- or biopsy-proved, involved at least two organ systems, and had been treated with the maximal tolerated medical therapy. Cellular proliferation, cytokine production, and phagocyte function were assessed in peripheral-blood cells. Interferon gamma was administered subcutaneously two or three times weekly in a dose of 25 to 50 micrograms per square meter of body-surface area in addition to antimycobacterial medications. Clinical effects were monitored by cultures, biopsies, radiographs, and in one patient a change in the need for paracentesis. RESULTS: In response to phytohemagglutinin, the production of interferon gamma by mononuclear cells from the patients was lower than in normal subjects (P < 0.001), whereas stimulation with ionomycin and phorbol myristate acetate led to normal production of interferon gamma in the patients. Within eight weeks of the start of interferon gamma therapy, all seven patients had marked clinical improvement, with abatement of fever, clearing of many lesions and quiescence of others, radiographic improvement, and a reduction in the need for paracentesis. CONCLUSIONS: Interferon gamma in combination with conventional therapy may be effective for some cases of refractory disseminated nontuberculous mycobacterial infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962
A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease
The International Chronic Granulomatous Disease Cooperative Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199102213240801 · Cited by 830
Nightingale, S. D., Byrd, L. T., Southern, P. M., Jockusch, J. D., Cal, S. X., & Wynne, B. A. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/165.6.1082 · Cited by 529
Smith, D. K., Neal, J. J., & Holmberg, S. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302113280601 · Cited by 357
Nathan, C. F., Kaplan, G., Levis, W. R., Nusrat, A., Witmer, M. D., Sherwin, S. A., Job, C. K., Horowitz, C. R., Steinman, R. M., & Cohn, Z. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198607033150102 · Cited by 323
Treatment of Visceral Leishmaniasis with Pentavalent Antimony and Interferon Gamma
Badaro, R., Falcoff, E., Badaro, F. S., Carvalho, E. M., Pedral-Sampaio, D., Barral, A., Carvalho, J. S., Barral-Netto, M., Brandely, M., Silva, L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220104 · Cited by 310
HORSBURGH, C. R., MASON, U. G., FARHI, D. C., & ISEMAN, M. D. (1985) · Medicine · doi:10.1097/00005792-198501000-00003 · Cited by 293
Duncan, R. A., von Reyn, C. F., Alliegro, G. M., Toossi, Z., Sugar, A. M., & Levitz, S. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302113280604 · Cited by 213
Sechler, J. M., Malech, H. L., White, C. J., & Gallin, J. I. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4874 · Cited by 175
Self-citationEzekowitz, R. A., Orkin, S. H., & Newburger, P. E. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113153 · Cited by 169
Cited by
A Mutation in the Interferon-γ –Receptor Gene and Susceptibility to Mycobacterial Infection
Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A., Williamson, R., & Levin, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352602 · Cited by 1,199
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Bustamante, J., Boisson-Dupuis, S., Abel, L., & Casanova, J.-L. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.09.008 · Cited by 684
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
Lucey, D. R., Clerici, M., & Shearer, G. M. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.532 · Cited by 666
Floto, R. A., Olivier, K. N., Saiman, L., Daley, C. L., Herrmann, J.-L., Nick, J. A., Noone, P. G., Bilton, D., Corris, P., Gibson, R. L., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207360 · Cited by 466
Metadata
- Authors
- Holland, S. M., Eisenstein, E. M., Kuhns, D. B., Turner, M. L., Fleisher, T. A., Strober, W., & Gallin, J. I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-05-12
- Volume
- 330
- Issue
- 19
- Pages
- 1348-1355
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1976205488
- Cited by
- 302
- References
- 18
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Refractory Disseminated Nontuberculous Mycobacterial Infection With Interferon Gamma: A Preliminary Report. https://app.cochat.ai/papers/10.1056/nejm199405123301904
- The paper
- Holland, S. M., Eisenstein, E. M., Kuhns, D. B., Turner, M. L., Fleisher, T. A., Strober, W., & Gallin, J. I. (1994). Treatment of Refractory Disseminated Nontuberculous Mycobacterial Infection With Interferon Gamma: A Preliminary Report. New England Journal of Medicine. https://doi.org/10.1056/nejm199405123301904
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.